These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22538621)

  • 1. Indacterol (Arcapta Neohaler) for COPD.
    Med Lett Drugs Ther; 2012 Apr; 54(1389):33-5. PubMed ID: 22538621
    [No Abstract]   [Full Text] [Related]  

  • 2. [Indacaterol (Onbrez Breezhaler), oral inhalation].
    Duh D; Tanret I
    J Pharm Belg; 2011 Dec; (4):127-8. PubMed ID: 22299240
    [No Abstract]   [Full Text] [Related]  

  • 3. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 4. Indacaterol.
    Donohue JF; Martinez FJ
    COPD; 2011 Oct; 8(5):327-8. PubMed ID: 21936681
    [No Abstract]   [Full Text] [Related]  

  • 5. Indacaterol: a novel long-acting β(2) -agonist.
    Ray SM; McMillen JC; Treadway SA; Helmer RS; Franks AS
    Pharmacotherapy; 2012 May; 32(5):456-74. PubMed ID: 22499359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of indacaterol during an acute exacerbation of COPD.
    Segreti A; Fiori E; Calzetta L; Sabatini M; Segreti V; Rogliani P; Cazzola M
    Pulm Pharmacol Ther; 2013 Dec; 26(6):630-4. PubMed ID: 23578980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ▾Indacaterol for COPD.
    Drug Ther Bull; 2012 May; 50(5):58-60. PubMed ID: 22573707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast, indacaterol maleate, and abiraterone acetate.
    Hussar DA; DePasquale J
    J Am Pharm Assoc (2003); 2011; 51(5):668-71. PubMed ID: 21896467
    [No Abstract]   [Full Text] [Related]  

  • 12. An update on the use of indacaterol in patients with COPD.
    Brienza NS; Amor-Carro O; Ramos-Barbón D
    Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indacaterol Novartis/skyePharma.
    Currie GP
    Curr Opin Investig Drugs; 2006 May; 7(5):457-63. PubMed ID: 16729723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
    Leiro-Fernández V; Priegue Carrera A; Fernández-Villar A
    Arch Bronconeumol; 2016 Dec; 52(12):622-623. PubMed ID: 27372542
    [No Abstract]   [Full Text] [Related]  

  • 16. The risks and benefits of indacaterol--the FDA's review.
    Chowdhury BA; Seymour SM; Michele TM; Durmowicz AG; Liu D; Rosebraugh CJ
    N Engl J Med; 2011 Dec; 365(24):2247-9. PubMed ID: 22168640
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
    Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indacaterol is a new once-daily beta2-agonist for treatment of COPD].
    Ulrik CS
    Ugeskr Laeger; 2010 Nov; 172(47):3260-3. PubMed ID: 21092722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medication of the month. Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease].
    Corhay JL; Louis R
    Rev Med Liege; 2011 Sep; 66(9):498-502. PubMed ID: 21995240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP
    Expert Opin Pharmacother; 2010 Aug; 11(12):2077-85. PubMed ID: 20642373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.